CD4 and herpes zoster: As compared with published results about treatment with other bDMARDs, the incidence rate of herpes zoster elevated in clinical trials and long-term extension studies [20].Although the mechanism by which tofacitinib cause herpes zoster still remains unclear, CD4 T cell function and regulation of interferons during viral infections are both suspected to be factors.